Some Indianapolis-area doctors fear a bill in the U.S. Senate would botch the way costs for tests and procedures are calculated, and ultimately
lead to a reimbursement system that works worse than the existing system.
Democratic lawmakers are seeking to stir up competition by stripping health insurers like Indianapolis-based WellPoint of
their protection from certain federal antitrust laws, although experts shrug off the effort as largely symbolic.
CEO John Lechleiter says Lilly’s pipeline has helped it rebound from significant patent losses three times during his 30-year
career at the company. He’s betting there will be a fourth.
Goodwill Industries executive Keith Reissaus has been tapped to run Washington, D.C.-based Leapfrog Group, an industry coalition.
Reissaus gained control of health care costs by giving employees incentives to care about their health.
Top Senate Democrats intend to try to strip the health insurance industry of its exemption from federal antitrust laws, according
to congressional officials, the latest evidence of a deepening struggle over President Barack Obama’s effort to overhaul the
health care industry.
Founder of medical device firm says Congress should fund network of low-cost clinics.
Fear of death may be causing Americans to expect too much from our medical system when it comes to prolonging the lives of
the old and infirm.
This flu season looks to provide us an inkling of the real dangers inherent in large-scale health care reform, most especially
a full-blown national health care option.
The health insurance industry’s sudden counterpunch to the Senate version of health reform echoed in Indiana and
opened a key issue for the rest of the debate: Will covering half of the country’s uninsured mean raising premiums for
the 85 percent of Americans who already have insurance?
As health care legislation
continues to wend its way through Congress, Indianapolis-area industry leaders still harbor strong
opinions about the issue. Five industry insiders discussed how to improve the health care system during
IBJ’s Power Breakfast Sept. 25 at the Westin Indianapolis.
Doctors are considering their options as health care reform gains momentum.
Specialists are clustering to focus on a single ailment, such as pain, to cut costs and improve quality of treatment.
Presenting five video excerpts from a free-wheeling panel discussion about health-care reform featuring five of the city’s
top minds and decision-makers. Reporter J.K. Wall moderates the IBJ’s Power Breakfast on Sept. 25, covering tort reform,illegal
immigrants, pay models and the role of insurance companies.
Presenting five video excerpts from a free-wheeling panel discussion about health-care reform featuring five of the city’s
top decision-makers. J.K. Wall moderates the IBJ’s Power Breakfast, covering tort reform,illegal immigrants, pay models and
insurance companies.
The insurance industry sharply escalated its criticism of the Senate health care bill Sunday, charging that the legislation
would shift costs to privately insured people, raising the price of a typical policy by hundreds, if not thousands, of dollars
annually.
The Indiana Division of Aging wants to change Medicaid rates to nursing homes to reward quality care and penalize the lack
of it, leaving the industry divided over whether to support the groundbreaking rule or to seek revisions and a slower phase-in.
Most business groups cheered when Sen. Max Baucus, D-Mont., introduced a health reform bill with no so-called public option,
a controversial government-run insurance plan for working adults. But there’s a big group that would like
to see it back on the table—hospitals.
The tool the administration is using to measure waste shows that expenses in Indianapolis might be low enough
not to get whacked. But the region isn’t performing so well that it’s likely to get much praise, either.
Eli Lilly and Co. and its peers might be back in Congress’ sights as lawmakers hunt for more ways to cut health care
costs. A new study in the influential Health Affairs journal concludes that European drugmakers operating
in markets with pharmaceutical price controls have produced proportionally more innovations than their U.S. counterparts.
If President Barack Obama gets what he wants in his health care plan — covering all Americans and barring insurers from
denying coverage — some analysts say individuals could wind up paying higher premiums.
